期刊文献+

血清YKL-40水平与Graves病患者甲状腺激素水平的相关性研究

Correlation Study between Serum YKL-40 Levels and Thyroid Hormone Levels in Patients with Graves'Disease
下载PDF
导出
摘要 目的探讨血清YKL-40水平与Graves病(Graves'disease,GD)患者甲状腺激素水平的相关性研究。方法选择2021年8月—2022年8月江南大学附属中心医院收治的142例新诊断的GD患者和137名健康人参加研究。检测血清中YKL-40水平,研究血清YKL-40水平与GD患者甲状腺激素水平的相关性。结果GD患者血清YKL-40显著高于健康对照组[(606.1±149.8)pg/mL vs(397.4±95.1)pg/mL],差异有统计学意义(t=13.837,P<0.001)。血清中YKL-40的浓度与血清中游离三碘甲腺原氨酸(free triiodothyronine,FT3)和血清游离甲状腺素(free thyroxine,FT4)浓度呈显著正相关性(r=0.440、0.468,P<0.001),与促甲状腺激素(thyroid stimulating hormone,TSH)浓度呈显著负相关性(r=-0.469,P<0.001)。结论YKL-40可能与GD的发病机制密切相关,同时与FT3和FT4也存在密切关系。 Objective To investigate the correlation between serum YKL-40 levels and thyroid hormone levels in pa‐tients with Graves'disease(GD).Methods A total of 142 newly diagnosed GD patients and 137 healthy people admit‐ted to the Central Hospital Affiliated to Jiangnan University from August 2021 to August 2022 were selected to partici‐pate in the study.The serum YKL-40 level was detected,and the correlation between serum YKL-40 level and thy‐roid hormone level in GD patients was studied.Results GD patients serum YKL 40 is significantly higher than healthy controls[(606.1±149.8)pg/mL vs(397.4±95.1)pg/mL],and the difference was statistically significant(t=13.837,P<0.001).The serum YKL-40 concentration was positively correlated with the serum free triiodothyronine(FT3)and free thyroxine(FT4)concentrations(r=0.440,0.468,P<0.001).And thyroid stimulating hormone(TSH)concentrations were significantly negative correlation(r=0.469,P<0.001).Conclusion YKL-40 may be closely related to the pathogenesis of GD,as well as to free T3(FT3)and T4(FT4).
作者 王雯 王卓平 WANG Wen;WANG Zhuoping(Department of Endocrinology and Metabolism,the Affiliated Central Hospital of Jiangnan University,Wuxi,Jiangsu Province,214000 China)
出处 《系统医学》 2023年第21期21-23,27,共4页 Systems Medicine
关键词 GRAVES病 YKL-40 甲状腺激素水平 Graves'disease YKL-40 Thyroid hormone level
  • 相关文献

参考文献4

二级参考文献55

  • 1王玉霞,孙永玉.脂肪内分泌与PCOS胰岛素抵抗的研究进展[J].国外医学(妇产科学分册),2004,31(5):291-294. 被引量:4
  • 2Bahn Chair RS,Burch HB,Cooper DS,et al.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J].Thyroid,2011,21(6):593-646.
  • 3George J.Kahaly,Luigi Bartalena,et al.The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis:a European perspective[J].Thyroid,2011,21(6):585-591.
  • 4Yamashita S,Amino N,Shong YK.The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines:viewpoints from Japan and Korea[J].Thyroid,2011,21(6):577-580.
  • 5Cooper DS,Doherty GM,Haugen BR,et al.American Thyroid Association(ATA)Guidelines Taskforce on thyroid nodules and differentiated cancer[J].Thyroid,2009,19(11)1167-1214.
  • 6Trdisk F,Tallstedt L,Abraham-Nordling M,et al.Thyroidassociated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131[J].J Clin Endocrinol Metab,2009,94(10):3700-3707.
  • 7Peters H,Fischer C,Bogner U,et al.Radioiodine therapy of Graves' hyperthyroidism:standard vs.calculated 131 iodine activity.Results from aprospective,randomized,multicentre study[J].Eur J Clin Invest,1995,25(3):186-193.
  • 8Costaghola S,Morgenthaler NG,Hoermann R,et al.Second generation assay for thyrotropin receptor antibodies has superior diagnostics ensitivity for Graves' disease[J].J Clin Endocrinol Metab,1999,84(1):90-97.
  • 9Cooper DS.Antithyroid drugs[J].N Engl J Med,2005,352(9):905-917.
  • 10Klein I,Becker D,Levey GS.Treatment of hyperthyroid disease[J].AnnInt Med,1994,121(4):281-288.

共引文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部